Levitt M, Sharma R N, Faiman C
Cancer Treat Rep. 1979 Aug;63(8):1327-30.
A dose of 125 mg of methylprednisolone was given iv each morning for 28 days to six patients with cancer. The posttreatment mean AM/PM serum cortisol (hydrocortisone) level of 19.55/11.27 microgram/dl showed a statistically significant (P less than 0.05) diurnal rhythm and did not differ from the pretreatment level (19.28/11.85 microgram/dl). The response to metyrapone (750 mg orally, every 4 hours X six doses) was assessed in five of the six patients before and after treatment. No abnormally low Compound S (11-deoxycortisol) levels were observed. The mean serum Compound S level (15.30 microgram/dl) achieved after treatment did not differ significantly from the pretreatment mean level (20.24 microgram/dl, P greater than 0.1). No adverse clinical effects were observed during or after this steroid treatment. Since significant hypothalamic-pituitary-adrenal suppression has not been demonstrated, this regimen appears to be safe for use in controlled studies of clinical efficacy.
每天早晨静脉注射125毫克甲泼尼龙，连续28天，对6名癌症患者进行治疗。治疗后上午/下午血清皮质醇（氢化可的松）平均水平为19.55/11.27微克/分升，显示出具有统计学意义（P<0.05）的昼夜节律，且与治疗前水平（19.28/11.85微克/分升）无差异。在治疗前后，对6名患者中的5名进行了甲吡酮（口服750毫克，每4小时一次，共6剂）反应评估。未观察到异常低的化合物S（11-脱氧皮质醇）水平。治疗后达到的血清化合物S平均水平（15.30微克/分升）与治疗前平均水平（20.24微克/分升，P>0.1）无显著差异。在这种类固醇治疗期间或之后未观察到不良临床效应。由于尚未证明存在显著的下丘脑-垂体-肾上腺抑制，该方案在临床疗效对照研究中似乎是安全的。
